AbCellera Biologics Inc. ABCL
Nov 6, 2026, 3:34 PM EST
- YTD
- +247.66%
- 1 year
- +162.47%
- Market cap
- 3.85B
- Revenue (ttm)
- 66.17M
- Profit margin
- -248.84%
- EPS (ttm)
- -0.54
- Shares out
- 324.05M
- Forward P/E
- -16.10
- YTD return
- +247.66%
- 1-year return
- +162.47%
- Volume
- 1.69M
- Avg volume
- 6.28M
- Open
- 11.48
- Previous close
- 11.13
- Day's range
- 11.38 – 11.98
- 52-week range
- 2.75 – 15.02
- Beta
- 1.59
- Analysts
- Strong Buy
- Price target
- 17.17 (+44.4%)
- Earnings date
- Nov 9, 2026
5D -0.23 (-1.90%)
Key statistics
- Enterprise value
- 3.33B
- PEG ratio
- 0.00
- Price / sales
- 60.11
- Price / book
- 4.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -76.30%
- Free cash flow
- -46.43M
- Total cash
- 540.10M
- Total debt
- 135.62M
- Return on equity
- -17.30%
- Short % of float
- 12.16%
- 50-day average
- 12.31
- 200-day average
- 6.93
Analyst view
Consensus: strong buy
- Target (low)
- 9.00
- Target (mean)
- 17.17
- Target (high)
- 30.00
- Strong buy2
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.17762.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.17064 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | -0.164 | -0.18 | -0.02 | -9.76% |
| May 11, 2026 | Mar 31, 2026 | -0.22 | -0.14 | +0.08 | +36.36% |
| Feb 24, 2026 | Dec 31, 2025 | -0.18 | -0.03 | +0.15 | +83.33% |
| Nov 6, 2025 | Sep 30, 2025 | -0.17 | -0.19 | -0.02 | -11.76% |
| Aug 7, 2025 | Jun 30, 2025 | -0.17 | -0.12 | +0.05 | +29.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Buy |
| Sep 29, 2026 | JP Morgan | init | — | Overweight |
| Aug 11, 2026 | Truist Securities | main | Buy | Buy |
| Aug 6, 2026 | Stifel | main | Buy | Buy |
| Aug 6, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jul 7, 2026 | Benchmark | up | Hold | Buy |
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- abcellera.com
News
UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18 
JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17 - Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target
AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause 
What'sGoing On With AbCellera Biologics Stock On Tuesday? 
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday 
What's Going on With AbCellera Biologics Stock On Wednesday? 
National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session - AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Your note
Sign in to keep a note on ABCL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BOOTH ANDREW | Chief Financial Officer | Purchase | Aug 13, 2026 | 613,759 |
| HANSEN CARL L.G. | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 24, 2024 | 56,984,000 |
| HAYDEN MICHAEL REUBEN | Director | Purchase | Aug 23, 2026 | 0 |
| MONTALBANO JOHN S. | Director | Purchase | Aug 17, 2026 | 256,000 |
| THERMOPYLAE HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 26, 2026 | 56,134,100 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 10.77% | 33,012,138 | 405.22M | Jun 29, 2026 |
| Capital World Investors | 4.43% | 13,588,349 | 166.80M | Jun 29, 2026 |
| Two Sigma Investments, LP | 3.40% | 10,437,431 | 128.12M | Jun 29, 2026 |
| TD Waterhouse Canada Inc. | 3.01% | 9,222,005 | 113.20M | Sep 29, 2026 |
| Bank of America Corporation | 2.00% | 6,141,539 | 75.39M | Jun 29, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.41% | 4,317,206 | 52.99M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 4.31% | 13,228,596 | 162.38M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.63% | 1,945,418 | 23.88M | Sep 29, 2026 |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 0.41% | 1,257,977 | 15.44M | Aug 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.34% | 1,053,900 | 12.94M | Jun 29, 2026 |
| NORTHERN LIGHTS FUND TRUST III-Counterpoint Quantitative Equity ETF | 0.32% | 971,643 | 11.93M | Jun 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 0.29% | 877,500 | 10.77M | Sep 29, 2026 |